Funds and ETFs Hepion Pharmaceuticals, Inc.

Equities

HEPA

US4268973025

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.49 USD -0.40% Intraday chart for Hepion Pharmaceuticals, Inc. +7.33% -23.15%
Hepion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and the treatment hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company's cyclophilin inhibitor, rencofilstat is developed to offer benefits to address multiple complex pathologies relate to advanced liver disease. The Company's rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The Company provides an artificial intelligence (AI) tool, AI-POWR, that allows the selection of novel drug targets, biomarkers, and appropriate patient populations. The components of AI-POWR include access to publicly available databases, and in-house genomic and multi-omic big.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.49 USD
Average target price
30 USD
Spread / Average Target
+1,104.82%
Consensus
  1. Stock
  2. Equities
  3. Stock Hepion Pharmaceuticals, Inc. - Nasdaq
  4. Funds and ETFs Hepion Pharmaceuticals, Inc.